Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Taysha Gene Therapies (TSHA) Other financing activities: 2022-2025

Historic Other financing activities for Taysha Gene Therapies (TSHA) over the last 4 years, with Sep 2025 value amounting to -$285,000.

  • Taysha Gene Therapies' Other financing activities fell 70.66% to -$285,000 in Q3 2025 from the same period last year, while for Sep 2025 it was -$204,000, marking a year-over-year decrease of 146.15%. This contributed to the annual value of -$167,000 for FY2024, which is 141.85% down from last year.
  • Per Taysha Gene Therapies' latest filing, its Other financing activities stood at -$285,000 for Q3 2025, which was down 341.53% from $118,000 recorded in Q2 2025.
  • In the past 5 years, Taysha Gene Therapies' Other financing activities ranged from a high of $652,000 in Q4 2023 and a low of -$640,000 during Q3 2023.
  • For the 3-year period, Taysha Gene Therapies' Other financing activities averaged around -$1,500, with its median value being -$21,500 (2024).
  • As far as peak fluctuations go, Taysha Gene Therapies' Other financing activities slumped by 1,222.81% in 2023, and later skyrocketed by 1,007.69% in 2025.
  • Quarterly analysis of 4 years shows Taysha Gene Therapies' Other financing activities stood at -$333,000 in 2022, then soared by 295.80% to $652,000 in 2023, then crashed by 93.40% to $43,000 in 2024, then crashed by 70.66% to -$285,000 in 2025.
  • Its Other financing activities stands at -$285,000 for Q3 2025, versus $118,000 for Q2 2025 and -$80,000 for Q1 2025.